Purpose: A low-pressure bladder in children with neuropathic bladder dysfunction can be achieved using anticholinergic medication. Due to the significant side effects of oral oxybutynin, our patients are treated with daily intravesical oxybutynin instillations. Newer oral anticholinergic medication, such as fesoterodine, claim to have fewer side effects in a once daily formulation. Because once-daily oral intake is easier than performing twice-daily intravesical instillations, we studied the effects of switching from intravesical oxybutynin to oral fesoterodine and compared the clinical response, urodynamic parameters and side effects. Patients and Methods: Twenty children (11 girls, 9 boys, 4–17 years) with neuropathic bladder dysfunction who perform clean intermittent catheterization and use intravesical oxybutynin instillations twice daily were included in this prospective study. Voiding diaries, a behavioural checklist, urodynamic investigations, vital signs and blood samples were evaluated at baseline during treatment with intravesical oxybutynin and repeated after 40 days of oral fesoterodine. Results: Out of 20, 13 (65%) children showed an identical objective dryness (pad-test), 2 (10%) improved and 5 (25%) got worse. Seven (35%) children reported equal dryness, 7 (35%) reported improvement and 6 (30%) reported that it got worse. From a urodynamic perspective, 13 (65%) children remained identical, 3 (15%) improved and 4 (20%) got worse. Four (20%) children reported a light to moderate dry mouth, 1 (5%) a headache, 1 (5%) behavioural changes during fesoterodine administration, 1 (5%) an increased appetite, 1 (5%) nausea and 1 (5%) hot flushes. Conclusions: The urodynamics after 40 days of fesoterodine were in 16 (80%) identical or better and could be a safe alternative for oxybutynin instillations in children with neuropathic bladder dysfunction.

Keywords:
Anticholinergic, Fesoterodine, Intravesical, Oxybutynin, Children, Neurogenic bladder, Neuropathic bladder
1.
Yeung CK, Sihoe JD.
Voiding dysfunction in children: non-neurogenic and neurogenic
. 9th ed. Campbell-Walsh Urology; 2007. pp. 3604–55.
2.
Austin PF, Bauer SB, Bower W, Chase J, Franco I, Hoebeke P, et al. The Standardization of Terminology of Lower Urinary Tract Function in Children and Adolescents: Update Report From the Standardization Committee of the International Children’s Continence Society.
Neurourol Urodyn
. 2016 Apr;35(4):471–81.
3.
Verpoorten C, Buyse GM. The neurogenic bladder: medical treatment.
Pediatr Nephrol
. 2008 May;23(5):717–25.
4.
Clayton DB, Brock JW 3rd. The urologist’s role in the management of spina bifida: a continuum of care.
Urology
. 2010 Jul;76(1):32–8.
5.
Andersson KE. Antimuscarinic mechanisms and the overactive detrusor: an update.
Eur Urol
. 2011 Mar;59(3):377–86.
6.
Franco I, Horowitz M, Grady R, Adams RC, de Jong TP, Lindert K, et al. Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction.
J Urol
. 2005 Jan;173(1):221–5.
7.
Buyse G, Waldeck K, Verpoorten C, Björk H, Casaer P, Andersson KE. Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism.
J Urol
. 1998 Sep;160(3 Pt 1):892–6.
8.
Schröder A, Albrecht U, Schnitker J, Reitz A, Stein R. Efficacy, safety, and tolerability of intravesically administered 0.1% oxybutynin hydrochloride solution in adult patients with neurogenic bladder: a randomized, prospective, controlled multi-center trial.
Neurourol Urodyn
. 2016 Jun;35(5):582–8.
9.
Palmer LS, Zebold K, Firlit CF, Kaplan WE. Complications of intravesical oxybutynin chloride therapy in the pediatric myelomeningocele population.
J Urol
. 1997 Feb;157(2):638–40.
10.
Mansfield KJ, Chandran JJ, Vaux KJ, Millard RJ, Christopoulos A, Mitchelson FJ, et al. Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa.
J Pharmacol Exp Ther
. 2009 Mar;328(3):893–9.
11.
Pfizer. Toviaz (fesoterodine fumarate): full prescribing information. 2012.
12.
Maruyama S, Oki T, Otsuka A, Shinbo H, Ozono S, Kageyama S, et al. Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder.
J Urol
. 2006 Jan;175(1):365–9.
13.
Malhotra B, Darsey E, Crownover P, Fang J, Glue P. Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers.
Br J Clin Pharmacol
. 2011 Aug;72(2):226–34.
14.
Yoshida A, Fuchihata Y, Kuraoka S, Osano A, Otsuka A, Ozono S, et al. Fesoterodine, its active metabolite, and tolterodine bind selectively to muscarinic receptors in human bladder mucosa and detrusor muscle.
Urology
. 2013 Apr;81(4):920.e1–5.
15.
Malhotra B, Gandelman K, Sachse R, Wood N, Michel MC. The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine.
Curr Med Chem
. 2009;16(33):4481–9.
16.
Malhotra B, El-Tahtawy A, Wang EQ, Darekar A, Cossons N, Crook TJ, et al. Dose-escalating study of the pharmacokinetics and tolerability of fesoterodine in children with overactive bladder.
J Pediatr Urol
. 2012 Aug;8(4):336–42.
17.
Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
BJU Int
. 2010 Jan;105(1):58–66.
18.
Ellsworth PI, Borgstein NG, Nijman RJ, Reddy PP. Use of tolterodine in children with neurogenic detrusor overactivity: relationship between dose and urodynamic response.
J Urol
. 2005 Oct;174(4 Pt 2):1647–51.
19.
Wyndaele JJ. Overactive bladder, differential diagnosis, and clinical utility of fesoterodine.
Int J Gen Med
. 2012;5:943–51.
20.
Guerra LA, Moher D, Sampson M, Barrowman N, Pike J, Leonard M. Intravesical oxybutynin for children with poorly compliant neurogenic bladder: a systematic review.
J Urol
. 2008 Sep;180(3):1091–7.
21.
Ferrara P, D’Aleo CM, Tarquini E, Salvatore S, Salvaggio E. Side-effects of oral or intravesical oxybutynin chloride in children with spina bifida.
BJU Int
. 2001 May;87(7):674–8.
22.
Marusteri M, Bacarea V. Comparing groups for statistical differences: how to choose the right statistical test?
Biochem Med (Zagreb)
. 2010;20:15–32.
23.
Bauer SB, Austin PF, Rawashdeh YF, de Jong TP, Franco I, Siggard C, et al.; International Children’s Continence Society. International Children’s Continence Society’s recommendations for initial diagnostic evaluation and follow-up in congenital neuropathic bladder and bowel dysfunction in children.
Neurourol Urodyn
. 2012 Jun;31(5):610–4.
24.
Rawashdeh YF, Austin P, Siggaard C, Bauer SB, Franco I, de Jong TP, et al.; International Children’s Continence Society. International Children’s Continence Society’s recommendations for therapeutic intervention in congenital neuropathic bladder and bowel dysfunction in children.
Neurourol Urodyn
. 2012 Jun;31(5):615–20.
25.
Lehnert T, Weisser M, Till H, Rolle U. The effects of long-term medical treatment combined with clean intermittent catheterization in children with neurogenic detrusor overactivity.
Int Urol Nephrol
. 2012 Apr;44(2):335–41.
26.
Yarker YE, Goa KL, Fitton A. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability.
Drugs Aging
. 1995 Mar;6(3):243–62.
27.
Goldenberg MM. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder.
Clin Ther
. 1999 Apr;21(4):634–42.
28.
Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ. Which anticholinergic drug for overactive bladder symptoms in adults. In: Madhuvrata P, editor.
Cochrane Database of Systematic Reviews
. Chichester, UK: John Wiley & Sons, Ltd; 2012.
29.
Youdim K, Kogan BA. Preliminary study of the safety and efficacy of extended-release oxybutynin in children.
Urology
. 2002 Mar;59(3):428–32.
30.
Di Stasi SM, Giannantoni A, Navarra P, -Capelli G, Storti L, Porena M, et al. -Intravesical oxybutynin: mode of action -assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl oxybutynin.
J Urol
. 2001 Dec;166(6):2232–6.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.